NeuroSense CFO Or Eisenberg files Form 3 holdings

NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg, detailing his existing equity interests in the company.

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg, detailing his existing equity interests in the company. The filing reports direct ownership of 573,126 Ordinary Shares, along with fully vested options and warrants over additional Ordinary Shares.

The Form 3 shows options to purchase 21,000 Ordinary Shares at an exercise price of $0.033 per share, expiring on June 21, 2031, which are noted as fully vested and exercisable. It also lists warrants to purchase 66,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, acquired in an August 15, 2024 private placement.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Eisenberg Or

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Warrants to purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 21,000 contracts (Direct); Warrants to purchase Ordinary Shares — 66,666 contracts (Direct); Ordinary Shares — 1,054,050 shares (Direct)

Footnotes (4)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
2. F2. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
3. F3. These options are fully vested and exercisable.
4. F4. On August 15, 2024, the Reporting Person acquired (i) 66,666 ordinary shares of the Company, no par value per share ("Ordinary Shares"), and (ii) warrants to purchase up to 66,666 Ordinary Shares at a combined purchase price of $0.75 per Ordinary Share and accompanying warrant, in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

Key Figures

Direct Ordinary Shares holding: 573,126 shares Options underlying shares: 21,000 shares Option exercise price: $0.033 per share +5 more

8 metrics

Direct Ordinary Shares holding 573,126 shares Reported direct ownership on Form 3

Options underlying shares 21,000 shares Options to purchase Ordinary Shares

Option exercise price $0.033 per share Exercise price for 21,000-share option grant

Option expiration June 21, 2031 Expiration date of options at $0.033

Warrants underlying shares 66,666 shares Warrants to purchase Ordinary Shares

Warrant exercise price $0.75 per share Exercise price for 66,666-share warrant position

Warrant expiration August 14, 2029 Expiration date of warrants at $0.75

Private placement purchase price $0.75 per share and warrant Combined purchase price in August 15, 2024 transaction

Key Terms

Form 3, Options to Purchase Ordinary Shares, warrants to purchase Ordinary Shares, 2018 Share Incentive Plan, +2 more

6 terms

Form 3 regulatory

"NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Options to Purchase Ordinary Shares financial

"The Form 3 shows options to purchase 21,000 Ordinary Shares at an exercise price"

warrants to purchase Ordinary Shares financial

"It also lists warrants to purchase 66,666 Ordinary Shares at an exercise price"

2018 Share Incentive Plan financial

"securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered"

Section 102 of the Israeli Tax Ordinance regulatory

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued"

private placement transaction financial

"in a private placement transaction pursuant to an exemption from the registration requirements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for NeuroSense Therapeutics (NRSN) disclose about Or Eisenberg?

The Form 3 discloses CFO Or Eisenberg’s existing equity interests in NeuroSense Therapeutics. It reports direct ownership of 573,126 Ordinary Shares and additional derivative positions through options and warrants linked to the company’s Ordinary Shares.

How many NeuroSense (NRSN) Ordinary Shares does Or Eisenberg directly hold?

The filing reports that Or Eisenberg directly holds 573,126 Ordinary Shares of NeuroSense Therapeutics. Additional Form 3 line items reflect other Ordinary Share positions and derivatives, but the 573,126-share entry is the largest reported direct Ordinary Share holding in his name.

What stock options for NeuroSense (NRSN) does Or Eisenberg report on Form 3?

Or Eisenberg reports options to purchase 21,000 NeuroSense Ordinary Shares at an exercise price of $0.033 per share, expiring June 21, 2031. A footnote states these options are fully vested and exercisable, meaning they can be converted into Ordinary Shares at that price.

What warrants tied to NeuroSense (NRSN) shares are listed in Or Eisenberg’s Form 3?

The Form 3 lists warrants to purchase 66,666 NeuroSense Ordinary Shares at an exercise price of $0.75 per share, expiring August 14, 2029. A footnote explains they were acquired in an August 15, 2024 private placement at a combined $0.75 per share and warrant.

What does the Form 3 say about NeuroSense (NRSN) equity issued under the 2018 Share Incentive Plan?

A footnote explains that, to qualify for certain Israeli tax benefits under Section 102, securities issued to employees or directors under the 2018 Share Incentive Plan must be registered in a trustee’s name, even though they are granted in connection with service to NeuroSense.

How do restricted shares for Or Eisenberg in NeuroSense (NRSN) vest according to the Form 3?

The Form 3 notes restricted shares vest 75% on April 16, 2027 and the remainder on October 16, 2027, if service continues. Vesting can accelerate and become fully vested upon achieving a specified business milestone in the restricted share agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:25 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Eisenberg Or

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	341,508	D
Ordinary Shares	139,416	D
Ordinary Shares	573,126(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)	07/01/2021	06/21/2031	Ordinary Shares	21,000(3)	$0.033	D
Warrants to purchase Ordinary Shares(4)	08/15/2024	08/14/2029	Ordinary Shares	66,666	$0.75(4)	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.

2. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

3. These options are fully vested and exercisable.

4. On August 15, 2024, the Reporting Person acquired (i) 66,666 ordinary shares of the Company, no par value per share ("Ordinary Shares"), and (ii) warrants to purchase up to 66,666 Ordinary Shares at a combined purchase price of $0.75 per Ordinary Share and accompanying warrant, in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

	/s/ Or Eisenberg	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)